EICHORCondition: Follicular Lymphoma · Diffuse Large B-Cell Lymphoma · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
This description comes directly from the study's public registry record.
David GHEZ · +33 1 42 11 42 40 · david.ghez@gustaveroussy.fr
Christophe MARZAC · +33 1 42 11 51 31 · christophe.marzac@gustaveroussy.fr
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen * Agreement to participate after receiving oral and written information on the study Exclusion Criteria: * History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma) * Treatment with a chemotherapy regimen different from RCHOP21
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Gustave Roussy | Villejuif, France | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06813573